Search Results for: Oral Delivery of Peptides by
Articles
DRUG DELIVERY - Oral Delivery of Peptides by Peptelligence Technology March 12, 2013
William Stern, PhD; Nozer Mehta, PhD; and Stephen Carl, PhD; review a highly developed, clinically proven platform technology that enables the oral delivery of peptides, overcoming the hurdles inherent to oral peptide delivery.
Biora Therapeutics Announces New Patent Covering its BioJet Liquid Jet Delivery Technology April 8, 2024
Claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract….
DRUG DELIVERY PLATFORM - VitalDose® EVA Implants for Systemic & Local Delivery of Therapeutics March 28, 2024
Cyonna Holmes, PhD, Karen Chen, MS, and Brian Duke explain how systemic delivery approaches that leverage continuous dosing can address adherence issues and improve drug effectiveness while minimizing adverse reactions, and how a localized delivery approach can minimize total drug exposure, reduce off-target toxicities, and overcome targeting issues.
Biora Therapeutics Progresses Research Collaboration for the BioJet Systemic Oral Delivery Platform January 2, 2024
Biora Therapeutics, Inc. recently announced its BioJet Systemic Oral Delivery Platform has met key performance milestones as part of its...Biora Therapeutics Announces New Patent for its NaviCap Targeted Oral Delivery Platform December 19, 2023
Biora Therapeutics, Inc. recently announced it received an Issue Notification from the US Patent and Trademark Office for a patent...Biora Therapeutics Announces New Research Collaboration for the BioJet Systemic Oral Delivery Platform December 11, 2023
Biora Therapeutics, Inc. recently announced a new research collaboration with a large pharmaceutical company for its BioJet Systemic Oral Delivery Platform. The new agreement provides funding….
FORMULATION FORUM - CUBOSOMES – The Next Generation of Lipid Nanoparticles for Drug Delivery October 2, 2023
Jim Huang, PhD, and Shaukat Ali, PhD, shed light on the design and formation of cubosomes with special focus on their applications for delivery of hydrophobic and hydrophilic small and large molecules, including oncology drugs and polynucleotides (DNA, mRNA, and siRNA).
LIPID-BASED EXCIPIENTS - Misconceptions About Lipid-Based Drug Delivery April 3, 2023
Rollie Fuller and Ron Permutt provide formulators confidence in using LBDDS as part of formulation development programs, by demonstrating their benefits and key functional mechanisms when used and addressing commonly misrepresented, misinterpreted, and misunderstood LBDDS topics.
Enteris BioPharma Presents Study of Ovarest® Demonstrating Oral Delivery Comparable to or Exceeding Injectable Leuprolide October 27, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned...Enteris BioPharma Announces Acceptance of Abstract for Oral Presentation at ASRM 2022 Scientific Congress & Expo August 1, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary...Apellis Expands R&D Collaboration With Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain June 22, 2022
Apellis Pharmaceuticals, Inc. and Affilogic recently announced the companies have expanded their research and development (R&D) collaboration, which was initially formed in 2018, to include the development of Nanofitins….
Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics May 5, 2022
Entera Bio Ltd. recently announced it recently filed multiple US patent applications to further strengthen the company’s patent protection and...NASAL DELIVERY - Improving Nasal Drug Delivery With Permeation Enhancing Technology March 1, 2022
Stuart Madden, PhD, focuses on the use of alkylsaccharides as absorption enhancers for nasal delivery of a wide range of drug types.
Rani Therapeutics Unveils High-Capacity RaniPill Device for Oral Delivery of Biologics February 23, 2022
Rani Therapeutics Holdings, Inc. recently announced the development of a high-capacity oral biologics device known as the RaniPill HC (High Capacity), capable of delivering up to….
FORMULATION FORUM - Formulation & Process of Lipid Nanoparticles for Delivery of Small Molecules & Biologicals January 17, 2022
Jim Huang, PhD, explains how recently, lipid nanoparticles have emerged as a drug delivery system for biologicals, especially for the COVID-19 mRNA vaccines in which LNPs play a vital role in transporting mRNA into the target cells.
DRUG DELIVERY - CAPRO(TM): A New Advance in Polymeric Drug Delivery October 4, 2021
Bob Wieden and Chun Wang, PhD, discuss how significant challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel polymeric drug delivery platform that overcomes a great many bioavailability and delivery obstacles.
Progenity & Ionis Pharmaceuticals Enter Agreement to Evaluate Progenity’s Ingestible Oral Biotherapeutics Technology for Delivery of Antisense Therapies April 8, 2021
Progenity, Inc. recently announced an agreement with Ionis Pharmaceuticals to evaluate the safety, tolerability, and performance of Progenity’s Oral Biotherapeutics Delivery System (OBDS) for oral systemic delivery of….
GLOBAL REPORT – 2020 Global Drug Delivery & Formulation Report: Part 2, Notable Drug Delivery and Formulation Product Approvals of 2020 March 29, 2021
In part 2 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, focuses on notable drug delivery and formulation product approvals.
ORAL MUCOSAL IMMUNOTHERAPY - Oral Mucosal Delivery of Allergenic Proteins for Inducing Tolerance in Food Allergic Individuals March 1, 2021
William R. Reisacher, MD, highlights some of the differences between food allergy immunotherapy via the oral mucosal route versus exposure through the stomach and intestines.
EXECUTIVE INTERVIEW - Enteris BioPharma: Pioneers in Oral Formulation Development September 30, 2020
Dr. Rajiv Khosla, CEO of Enteris BioPharma, discusses how his company’s innovative oral formulation technology is helping the pharmaceutical industry overcome the hurdle of low bioavailability to reshape treatment categories and expand market opportunities with minimal financial and regulatory risks.
WHITEPAPER - Key Considerations in Oral Delivery of Peptides – Factors to Consider While Evaluating Oral Administration
Peptide therapeutics are a hot topic in pharmaceutical R&D. While most peptides are administered parenterally, oral delivery of peptide therapeutics...Where Do We Stand on Poorly Soluble Drugs and Peptides in Oral Delivery?
The Rule of 5 suggests that, for oral bioavailability, a better chance for oral absorption is obtained when the molecules are within the parameters of the Rule of 5’. However, the pharmaceutical industry is achieving oral efficacy with drugs that exceed….
WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination
This paper covers the benefits of the LBF and capsules combination in dosage form developments, an efficient technology platform to bring efficient and differentiated products to the market.
WHITEPAPER: Optimizing Oral Drug Delivery Using Zydis® Orally Disintegrating Tablet Technology to Address Patient Challenges
Many patients prefer conventional tablets for the administration of medications, but some geriatric and pediatric patients and those with altered...
